Regulus Therapeutics Inc. (RGLS)

Market Cap	544.87M
Revenue (ttm)	n/a
Net Income (ttm)	-47.52M
Shares Out	69.23M
EPS (ttm)	-0.72
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,013,211
Open	7.86
Previous Close	7.87
Day's Range	7.82 - 7.90
52-Week Range	0.83 - 8.20
Beta	0.50
Analysts	Buy
Price Target	8.50 (+8.01%)
Earnings Date	May 8, 2025

About RGLS

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. The company develops farabursen, an anti-miR oligonucleotide targeting miR-17 in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. It is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. The company has a license and collaboration agreement with Alnylam Pharma...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 4, 2012
• Employees: 34
• Stock Exchange: NASDAQ
• Ticker Symbol: RGLS
• Website: https://www.regulusrx.com

Analyst Forecast

According to 6 analysts, the average rating for RGLS stock is "Buy." The 12-month stock price forecast is $8.5, which is an increase of 8.01% from the latest price.

Price Target

$8.5

(8.01% upside)

Analyst Consensus: Buy